In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Xanthon Inc.

Latest From Xanthon Inc.

The Next Step in Clinical Genetic Testing

Start-ups are scrambling to develop methods for analyzing genetic information, but most of their efforts are directed at the research market. Only a handful of companies are seriously looking at improving the process in the clinical lab. Their biggest challenges: overcoming PCR's dominance and distinguishing themselves from competitors. The field can't really take off, however, until new applications of genetic tests show medical value.

BioPharmaceutical Medical Device

Novalon Pharmaceutical

Ultra-high-throughput screening


Xanthon Inc.

Molecular Diagnostics. Xanthon claims it is developing a platform technology that will allow target squences of DNA or RNA to be detected with far less handling than PCR now requires. The technology takes advantage of the electrochemical properties of DNA. Xanthon attaches a membrane to an electrode and probes to the membrane. If a target sequence is present in the sample exposed to the membrane, it will bind, or hybridize there.

Medical Device
See All

Company Information

  • Industry
  • Biotechnology
  • Research, Analytical Equipment & Supplies